Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

Abroad (travel likely)RecruitingPHASE1

Conditions

Influenza Prevention · Seasonal Influenza

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (VRC Clinic) · vaccines@nih.gov · 301-451-8715

Study leads

Lasonji A Holman, C.R.N.P.
Principal Investigator
National Institute of Allergy and Infectious Diseases (NIAID)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting

Influenza

Abroad (travel likely)RecruitingPHASE3

Beijing, China · Beijing, China

Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza

Influenza

Abroad (travel likely)RecruitingPHASE3

Hanzhou, China

Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults

Influenza Prevention · Pandemic Influenza Prevention

Abroad (travel likely)RecruitingPHASE1

Bethesda, United States